Mar 25, 2025
 in 
Hot Stocks 🔥

Tonix Pharmaceuticals Soaring - New Fibromyalgia Drug | Nemo

Name of opportunity: 👀

Tonix Pharmaceuticals Holding Corp 

New drug for fibromyalgia management in process 💊

Tonix Pharmaceuticals has seen a price increase over the past day, as the stock’s value has gone up by 32.48% in the past day. The reason behind this price surge might be because the company recently announced that the FDA will not require an Advisory Committee meeting to discuss the new drug application (NDA) for fibromyalgia drug, TNX-102 SL. 

Tonix Pharmaceuticals is a growth stock that is currently generating modest revenue and cash flow. Analysts are calling this stock a ‘buy’ as of right now. 

How hot is this investment opportunity? 🔥🔥🔥

Analysts predict the price of Tonix Pharmaceuticals Holding Corp. might increase from $30.51 to $66.17 in the next 12 months. If you invested $1000, you might profit $1168.69.

TNX-102 SL is a new drug in development by Tonix Pharmaceuticals that aims to help treat those suffering with fibromyalgia. If this treatment gets approved, it’ll be the first treatment for fibromyalgia in 15 years. Tonix Pharmaceuticals have said they maintain their PDUFA goal date of August 15, 2025, which means commercial release of this drug might be coming up in the last quarter of 2025. This news might have created positive sentiment for Tonix Pharmaceuticals, which might be the driving factor behind its stock price increase. 

Tonix Pharmaceuticals specialises in treatments for chronic disorders of the Central Nervous System, immunology, treatments for rare diseases, and vaccines for infectious diseases. The company has two medicines currently available on the market, which are both treatments for migraine.

Pharmaceutical company 🧬

Tonix Pharmaceuticals is a pharmaceutical company that is headquartered in Chatham, New Jersey, United States. The company focuses on repurposed drugs for central nervous system (CNS) conditions.

Which neme?: 🔍

Top Gainers Today’, ‘Stocks On The Move

Download Nemo Money to check out Tonix Pharmaceuticals New users can grab our registration bonus up to a maximum of $50 on first deposit. Terms and conditions apply.

Han Tan

Han Tan is Chief Market Analyst at Nemo.money, bringing over a decade of experience in financial markets as both a seasoned journalist and analyst. Known for his sharp insights into stocks, currencies, and commodities, Han has become a familiar face to national audiences through appearances on Bloomberg TV Malaysia, BFM 89.9, and NTV7 — earning him a trusted reputation in financial media. Before joining Nemo, Han served as Market Analyst at Exinity Group from 2019, where his commentary on macroeconomic trends and market-moving news was regularly featured by global outlets including Reuters, Bloomberg, CNN, BBC, and AFP. Today, Han brings that same clarity and depth to Nemo’s community, delivering content-led ideas that empower first-time investors to confidently navigate global markets.